Afshin Fathi1, Mehrdad Mirzarahimi1, Homa Far Ajkhah2. 1. Associate Professor in Pediatrics, Department of Pediatrics, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran. 2. General Practitioner, Ardabil University of Medical Sciences, Ardabil, Iran.
Abstract
OBJECTIVE: The aim of this study was to investigate the outcome of chemotherapeutic regimen by high-risk pre-B-cell potocol in ALL children. METHODS: The cross-sectional study was conducted on 55 children who were treated with the Children Oncology Group (COG) protocol from September 2010 to February 2015 to evaluate the chemotherapeutic regimen results. RESULTS: There was a complete recovery rate of 76.4% during the first week after treatment. Three-year overall survival was 85.5% and five-year overall survival was 81%. Relapse rate after first remission was 20% and death after relapse was 50%. Thirty percent of total deaths were at the induction period. All of the deceased cases died due to sepsis. CONCLUSION: Results showed that the survival rate increased. By choosing the COG protocol and by controlling infection in patients without considering the risk group we can improve survival rates.
OBJECTIVE: The aim of this study was to investigate the outcome of chemotherapeutic regimen by high-risk pre-B-cell potocol in ALL children. METHODS: The cross-sectional study was conducted on 55 children who were treated with the Children Oncology Group (COG) protocol from September 2010 to February 2015 to evaluate the chemotherapeutic regimen results. RESULTS: There was a complete recovery rate of 76.4% during the first week after treatment. Three-year overall survival was 85.5% and five-year overall survival was 81%. Relapse rate after first remission was 20% and death after relapse was 50%. Thirty percent of total deaths were at the induction period. All of the deceased cases died due to sepsis. CONCLUSION: Results showed that the survival rate increased. By choosing the COG protocol and by controlling infection in patients without considering the risk group we can improve survival rates.
Authors: Shu Xiao Ou; Dehui Han; Richard K Severson; Zhi Chen; Joseph P Neglia; Gregory H Reaman; Jonathan D Buckley; Leslie L Robison Journal: Cancer Causes Control Date: 2002-02 Impact factor: 2.506